Ipca slumps after US import alert, ripple effect fears
This article was originally published in Scrip
Shares of Ipca Laboratories fell sharply following news of an FDA import alert against the company's active pharmaceutical ingredients (APls) unit in Ratlam and concerns on whether other international regulators may follow suit.
You may also be interested in...
India’s Ipca is boosting its API business with a deal to acquire local firm Ramdev Chemical for INR1.1bn in cash.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.